KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 1 filers reported holding KINNATE BIOPHARMA INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 6.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $14,989 | -57.0% | 10,706 | -7.0% | 0.00% | -100.0% |
| Q2 2023 | $34,896 | +174380.0% | 11,517 | +272.2% | 0.00% | 0.0% |
| Q1 2023 | $20 | +400.0% | 3,094 | +349.7% | 0.00% | – |
| Q4 2022 | $4 | -100.0% | 688 | -90.1% | 0.00% | -100.0% |
| Q3 2022 | $83,000 | +245.8% | 6,926 | +263.6% | 0.00% | 0.0% |
| Q2 2022 | $24,000 | +166.7% | 1,905 | +141.8% | 0.00% | – |
| Q1 2022 | $9,000 | -60.9% | 788 | -40.9% | 0.00% | – |
| Q4 2021 | $23,000 | +91.7% | 1,333 | +150.6% | 0.00% | – |
| Q3 2021 | $12,000 | -20.0% | 532 | -17.9% | 0.00% | – |
| Q2 2021 | $15,000 | -25.0% | 648 | -0.3% | 0.00% | – |
| Q1 2021 | $20,000 | – | 650 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 9,671,643 | $384,738,000 | 41.79% |
| Foresite Capital Management V, LLC | 875,001 | $34,808,000 | 25.78% |
| Vida Ventures Advisors, LLC | 2,747,074 | $109,279,000 | 22.43% |
| VR Adviser, LLC | 1,473,014 | $58,596,000 | 8.62% |
| RA Capital Management | 3,593,052 | $142,932,000 | 2.00% |
| Logos Global Management LP | 569,602 | $22,659,000 | 1.94% |
| Boxer Capital, LLC | 1,064,665 | $42,352,000 | 1.36% |
| Orbimed Advisors | 3,847,929 | $153,071,000 | 1.34% |
| HARVARD MANAGEMENT CO INC | 498,001 | $19,810,000 | 1.07% |
| DAFNA Capital Management LLC | 68,121 | $2,710,000 | 0.81% |